All News

Md Yuzaiful Md Yusof Tweet
Yuz6Yusof
In patients with #SLE who attained LLDAS, a retrospective cohort study by Dr Cunha identified predictors of flares including anti-RNP +ve, concomitant immunosuppressant and oral prednisolone. Important to account these during follow-up #EULAR2021 #POS0105 @RheumNow
Md Yuzaiful Md Yusof Tweet
Yuz6Yusof
Promising preclinical data of novel dual BAFF/APRIL inihibitor ALPN-303 re:efficacy & immunomodulatory activity vs TACI-i. Could deplete plasma cell compared to anti-CD20 mAbs in #SLE. Be interesting to see how it’ll fare in future clinical trials #EULAR2021 #OP0039 @RheumNow https://t.co/LnQzO67gwI
Eric Dein Tweet
ejdein1
Dr. Tani: Who has trouble tapering below 5mg/d prednisone in SLE ☑️Older patients ☑️High disease activity ☑️Skin and MSK manifestations ☑️Pts treated before 2000. Try to avoid long-term steroid usage early in the disease course, as it gets harder over time. #EULAR2021, @RheumNow
k dao Tweet
KDAO2011
Longitudinal UK SLE inception cohort 273 pts found: 👉⬆️damage in 1st 3 yrs b/f stabilizing at lower rate 👉mortality uncommon in 1st 12 yrs, but can occur w/in 5 yrs of Dx. 👉unexpected⬆️mortality in Caucasians 38% deaths IHD, 23% infx Abst#0111 #EULAR2021 @rheumnow @Lupusdoc https://t.co/wUwWaB4V2R
k dao Tweet
KDAO2011

Can you predict flares in SLE pts who achieved LLDAS? Retrospec cohort study from Portugal over 3 years of 292 pts who were in LLDAS, 31% flared. Flares seen more in: 👉pts who require ongoing Rx w/ immmunosuppr, GCs 👉pt w/+RNP Abst#0105 #EULAR2021 @RheumNow https://t.co/xfBqGh4pPP

k dao Tweet
KDAO2011
C3 and C4⬆️in SLE pregnancy like they would in pregnancies w/o SLE! French GR2 prospective study of 290 SLE pregnancies quantifies mean C3 value⬆️by 28%, C4⬆️by 11% from 1st ➡️3rd trimester. Remember this when assessing disease activity. #EULAR2021 Abstr #0103 @rheumnow https://t.co/TXjO4mjNJE
k dao Tweet
KDAO2011
Definition of LLDAS: "A state assc w/low likelihood of adverse outcome, considering disease activity and medication safety; it must be favorable, deployable, feasible, and attainable," - Dr. E Morand #EULAR2021 @RheumNow https://t.co/oMMU3AjhmX
k dao Tweet
KDAO2011
Dr. G Robinson Abstr#OP0013 on sex link b/t autoimmune & CV risk 👉Hormones drive funx change in Treg transciptome 👉anti-inflamm Tregs⬆️in males 👉Tregs are more suppressive in males 👉Treg transciptome profile altered b/t males & females in autoimmunity #EULAR2021 @rheumnow https://t.co/p4Awfu2hiK
k dao Tweet
KDAO2011
Prof A Doria introduces SLE-DAS, a new instrument to measure Lupus activity that is continuous and highly sensitive to changes in dz activity #EULAR2021 @rheumnow Watch the oral presentation 6/4/21 Abst#OP0297 https://t.co/gE9QhLL1oj
k dao Tweet
KDAO2011
What is your treat to target for lupus patients? #EULAR2021 @rheumnow
k dao Tweet
KDAO2011
Prof Van Vollenhoven reveals the Definition of Remission in SLE (DORIS 2021): treating SLE to target #EULAR2021 @rheumnow 👉SLEDAI=0 👉MD global<0.5 👉dsDNA, C3/C4 does not matter 👉prednisone <=5 mg/d, stable meds 👉remission can be met at any point (duration not required https://t.co/TwusJkXR19
Dr. John Cush Tweet
RheumNow
Top May Tweet: Belimumab now approved in the EU for lupus nephritis. The EMA has approved intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis https://t.co/Twbe1ClT5w
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×